Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
Clinical factors associated with treatment noncompliance in euthymic bipolar patients.
BACKGROUND Noncompliance with medication is a very common feature among bipolar patients . Rates of poor compliance may reach 64 % for bipolar disorders , and noncompliance is the most frequent cause of recurrence . Knowledge of the clinical factors associated with noncompliance would enhance clinical management and the design of strategies to achieve a better outcome for bipolar patients . Although most patients withdraw from medication during maintenance treatment , compliance studies in euthymic bipolar sample s are scarce . METHOD Compliance treatment and its clinical correlates were assessed at the end of 2-year follow-up in 200 patients meeting Research Diagnostic Criteria for bipolar I or bipolar II disorder by means of compliance-focused interviews , measurements of plasma concentrations of mood stabilizers  , and 2 structured interviews : the Schedule for Affective Disorders and Schizophrenia and the Structured Clinical Interview for DSM-III-R Axis II disorders . Well-compliant patients and poorly compliant patients were compared with respect to several clinical and treatment variables . RESULTS The rate of mildly and poorly compliant patients was close to 40 % . Comorbidity with personality disorders was strongly associated with poor compliance . Poorly compliant patients had a higher number of previous hospitalizations , but reported fewer previous episodes . The type of treatment was not associated with compliance . CONCLUSION Clinical factors , especially comorbidity with personality disorders , are more relevant for treatment compliance than other issues such as the nature of pharmacologic treatment . Compliant patients may have a better outcome in terms of number of hospitalizations , but not necessarily with respect to the number of episodes . Bipolar patients , especially those with personality disorders , should be monitored for treatment compliance
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .